The estimated Net Worth of Aaron I. Davis is at least 156 百万$ dollars as of 9 May 2022. Mr. Davis owns over 663,000 units of Mirati Therapeutics Inc stock worth over 126,443,205$ and over the last 7 years he sold MRTX stock worth over 29,078,270$. In addition, he makes 579,671$ as Independent Director at Mirati Therapeutics Inc.
Aaron has made over 14 trades of the Mirati Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 663,000 units of MRTX stock worth 13,949,520$ on 9 May 2022.
The largest trade he's ever made was buying 1,425,000 units of Mirati Therapeutics Inc stock on 28 July 2020 worth over 27,075,000$. On average, Aaron trades about 247,230 units every 60 days since 2017. As of 9 May 2022 he still owns at least 2,154,058 units of Mirati Therapeutics Inc stock.
You can see the complete history of Mr. Davis stock trades at the bottom of the page.
Aaron I. Davis serves as Independent Director of the Company. Mr. Davis has served as a member of our Board of Directors since December 2018. Mr. Davis co-founded Boxer Capital, LLC (“Boxer Capital”), the healthcare arm of the Tavistock Group, where he has served as portfolio manager since 2005 and as Chief Executive Officer since 2012. At Boxer Capital, Mr. Davis is responsible for identifying, evaluating and structuring investment opportunities in private and public biotechnology companies. Since 2016, Mr. Davis has served as the Executive Chairman of CiVi Biopharma, Inc. and as a member of the Board of Directors of Odonate Therapeutics, Inc. (NASDAQ:ODT) and Sojournix, Inc. From 2006 to 2008, he served as a member of the Board of Directors of Kalypsys, Inc. Prior to joining the Tavistock Group, Mr. Davis worked in the Global Healthcare Investment Banking and Private Equity Groups at UBS Warburg, LLC. Mr. Davis received an M.A. degree in biotechnology from Columbia University and a B.B.A. degree in finance from Emory University.
As the Independent Director of Mirati Therapeutics Inc, the total compensation of Aaron Davis at Mirati Therapeutics Inc is 579,671$. There are 12 executives at Mirati Therapeutics Inc getting paid more, with Charles Baum having the highest compensation of 8,484,390$.
Aaron Davis is 42, he's been the Independent Director of Mirati Therapeutics Inc since 2018. There are 18 older and 1 younger executives at Mirati Therapeutics Inc. The oldest executive at Mirati Therapeutics Inc is Bruce Carter, 76, who is the Independent Director.
Aaron's mailing address filed with the SEC is C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN, MA, 02472.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over 179,669,845$ worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth 186,410,608$ . The most active insiders traders include Healthcare Master Fund Ltd ...、Capital Advisors Llc Aghaza...、Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of 5,885,145$. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth 94,255$.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: